Helicobacter pylori eradication in renal recipient: Triple or quadruple therapy?

Acta Medica Iranica

Volumn 52, Issue 4, 2014, Pages 271-274

  Hosseini, Seyed Mousal Reza ^a   Sharifipoor, Farzane ^b   Nazemian, Fateme ^b   Ghanei, Hossein ^a   Zivarifar, Hamid Reza ^c   Fakharian, Tahereh ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dyspepsia; Helicobacter pylori; Quadruple therapy; Renal transplantation; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; GRAFT RECIPIENT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; KIDNEY TRANSPLANTATION; PREVALENCE; RAPID UREASE TEST; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BREATH TEST;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BREATH TESTS; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOCOMPROMISED HOST; IRAN; KIDNEY TRANSPLANTATION; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PROTON PUMP INHIBITORS; TETRACYCLINE; TREATMENT OUTCOME;

EID: 84900020959     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005;18(6):643-50.
2. Garvin PJ, Carney K, Castaneda M, et al. Peptic ulcer disease following transplantation: the role of cimetidine. Am J Surg 1982;144(5):545-8.
3. Jarowenko MV, Van Buren CT, Kramer WG, et al. Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation 1986;42(3):311-2.
4. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335(8700):1233-5.
5. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116(9):705-8.
6. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1(8390):1311-5.
7. Asl MK, Nasri H. Prevalence of Helicobacter pylori infection in maintenance hemodialysis patients with nonulcer dyspepsia. Saudi J Kidney Dis Transpl 2009;20(2):223-6.
8. Teenan RP, Burgoyne M, Brown IL, et al. Helicobacter pylori in renal transplant recipients. Transplantation 1993;56(1):100-3.
9. Davenport A, Shallcross TM, Crabtree JE, et al. Prevalence of Helicobacter pylori in patients with endstage renal failure and renal transplant recipients. Nephron 1991;59(4):597-601.
10. Sarkio S, Rautelin H, Kyllonen L, et al. Should Helicobacter pylori infection be treated before kidney transplantation? Nephrol Dial Transplant 2001;16(10):2053-7.
11. Yildiz A, Besisik F, Akkaya V, et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant 1999;13(1 Pt 1):13-6.
12. Ozgur O, Boyacioglu S, Ozdogan M, et al. Helicobacter pylori infection in haemodialysis patients and renal transplant recipients. Nephrol Dial Transplant 1997;12(2):289-91.
13. Abu Farsakh NA, Rababaa M, Abu Farsakh H. Symptomatic, endoscopic and histological assessment of upper gastrointestinal tract in renal transplant recipients. Indian J Gastroenterol 2001;20(1):9-12.
14. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133(3):985-1001.
15. Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6(11):699-709.
16. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161(9):1217-20.
17. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136(1):13-24.
18. Moradimoghadam F, Khosravi Khorashad A, Mokhtarifar A. Comparison between quadruples therapy and triple therapy for eradication of Helicobacter Pylori in patients with chronic dyspepsia. Horizon Med Sci 2009;14(4):13-18.
19. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14(11):1237-43.
20. Choi J, Jang JY, Kim JS, et al. Efficacy of two triple eradication regimens in children with Helicobacter pylori infection. J Korean Med Sci 2006;21(6):1037-40.
21. Catalano F, Catanzaro R, Bentivegna C, et al. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Aliment Pharmacol Ther 1998;12(1):59-62.